Genetic polymorphism and serotonergic antidepressant related sexual dysfunctio

Not Applicable

Recruiting

• Conditions: Sexual dysfunction; Major depressive disorder; Dysthymic disorder; Mental Health - Other mental health disorders; Mental Health - Depression; Renal and Urogenital - Other renal and urogenital disorders

• Registration Number: ACTRN12611000689976
• Lead Sponsor: Chih-Sung Liang

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-07
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 100

Inclusion Criteria

1. being diagnosed with major depressive disorder or dysthymic disorder (according to DSM-IV-TR diagnostic criteria)
2. being aged of 18-40
3. receiving serotonergic antidepressant, including sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, duloxetine, escitalopram, milnacipran
4. willing to engage in sexual activity, alone or with a partner, at least weekly for the duration of the study

Exclusion Criteria

1. receiving other medications that may cause sexual dysfunction, such as antipsychotics and mood stablizers
2. having any serious medical condition that affects sexual functioning such as epilepsy, serious head injury, brain tumor, HIV infection, Parkinson's disease, dementia, multiple sclerosis, or other neurological disorder
3. being comorbidity with substance abuse
4. developing sexual dysfunction before psychiatric illness

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Hamilton Rating Scale for Depression (HAMD) is used for assessment of depression status, and sexual dysfunction is rated using the Arizona Sexual Experience Scale (ASEX). Genomic DNA will be isolated from buccal cells collected with cheek brush. We use polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for genotyping single nucleotide polymorphisms, that is, A(-1438)G polymorphism of 5-hydroxytryptamine 2a receptor.[We assess the participants at baseline and week 4. We anticipate that the study will be completed within three months.]

Secondary Outcome Measures

Name	Time	Method
The association between treatment response and gene polymorphism is measured as the secondary outcome. Treatment response is assessed by using the changes in HAMD.[We assess the participants at baseline and week 4. We anticipate that the study will be completed within three months.]